Back to search results

ROSE Study: Understanding Recovery After Intracerebral Hemorrhage

This observational study, called ROSE, is looking at how people recover after an intracerebral hemorrhage (ICH), which is bleeding in the brain. Researchers want to understand why some people experience a decline in their thinking abilities (cognitive impairment) after an ICH. They will follow 250 participants who have had an ICH to see if changes in their brain scans (neuroimaging) or signs of inflammation (measured by RNA-sequencing) are linked to problems with memory and thinking. You may be able to join if you are 18 or older and have had a deep, subcortical, or lobar ICH that wasn't caused by trauma, a brain tumor, or a vascular problem. The study aims to understand what predicts recovery and progressive decline after an ICH.

Study design
This is an observational study following 250 participants. It is not testing a specific treatment, but rather observing participants over time.
What's involved
Participants will have advanced brain scans (neuroimaging) at 12-24 months after their stroke. They will also have evaluations of their movement and thinking abilities at the beginning of the study, and then again 6 months and 12 months later.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for cognitive changes for up to 36 months on average.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05089331

ROSE-Longitudinal Assessment With Neuroimaging

Active, Not Recruiting
Not specifiedAges 18+Observational
State University of New York at Buffalo
~250 participants
Updated 2026-07-01 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Determination of whether progressive cognitive impairment correlates with CVD and AA markers
Measured over Ongoing/completed by September 2024
+1 more outcome measured

Conditions

Intracerebral Hemorrhage

Explore related trials

Cerebral Hemorrhage

Where it's being run

7 sites across 7 states
Illinois1
Kentucky1
Maryland1
New York1
North Carolina1
Ohio1
Texas1

Study leadership

  • Daniel Woo, MD, MS · PRINCIPAL_INVESTIGATOR · State University of New York at Buffalo

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or greater, fulfillment of the criteria for Deep, Subcortical or Lobar Intracerebral Hemorrhage
No evidence of trauma, vascular malformation or aneurysm, or brain tumor as a cause of ICH.
Ability of the patient or legal representative to provide informed consent

Exclusion

Brainstem or Cerebellar ICH
Patients Severely Affected by the ICH, Early Mortality, Hospice, or Withdraw of Care NOT eligible for ROS

What this trial measures

  • Determination of whether progressive cognitive impairment correlates with CVD and AA markersOngoing/completed by September 2024

    Each subject has a baseline # Tesla (3T) MRI with DTI along with blinded central measurement of cerebral small vessel disease parameters. The current proposal is specifically designed to address these potential hypotheses by a comprehensive evaluation of detailed neurocognitive evaluations, baseline and long-term follow-up neuroimaging markers of CSVD and CAA as well as RNA sequencing of serum leukocytes for markers of inflammation.

  • Determination of whether inflammation as measured by RNA-sequencing markers of inflammation correlates with progressive cognitive impairmentOngoing/completed by September 2024

    The current proposal is specifically designed to address these potential hypotheses by a comprehensive evaluation of detailed neurocognitive evaluations, baseline and long-term follow-up neuroimaging markers of CSVD and CAA as well as RNA sequencing of serum leukocytes for markers of inflammation. If the occurrence of progressive cognitive decline is caused by inflammation from the ICH itself, those with cognitive decline should have chronically increased expression of inflammation compared to those without cognitive decline, where inflammatory markers normalize. Our preliminary data suggests a role of interleukin-8 as increased in expression after ICH.